NCT02267525View on ClinicalTrials.gov

The Diabetic and Idiopathic Gastroparesis Efficacy, Safety, and Tolerability (DIGEST) Study

PHASE2CompletedINTERVENTIONAL
Enrollment

233

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

June 30, 2017

Study Completion Date

June 30, 2017

Conditions
Gastroparesis
Interventions
DRUG

Velusetrag

DRUG

Placebo

Sponsors

Collaborators (1)

Alfasigma S.p.A.
All Listed Sponsors
collaborator

Alfasigma S.p.A.

INDUSTRY

lead

Theravance Biopharma

INDUSTRY